Liminal Biosciences

Liminal Biosciences Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for diseases with significant unmet medical needs. It operates through two main segments: Small Molecule Therapeutics and Plasma Derived Therapeutics. The Small Molecule Therapeutics segment's lead candidate, fezagepras, targets idiopathic pulmonary fibrosis, respiratory diseases, and Alström Syndrome. In the Plasma Derived Therapeutics segment, the company offers a Plasma Protein Purification System, which is designed for the extraction and purification of therapeutic proteins from human plasma, and is also developing Ryplazim for congenital plasminogen deficiency. Liminal Biosciences employs a data-driven approach to develop unique small molecule therapeutics aimed at various conditions, including fibrosis, anemia, cancer, and autoimmune diseases. The company operates in Canada, the United Kingdom, and the United States, and is headquartered in Laval, Canada. Founded in 1994, it was previously known as Prometic Life Sciences Inc. before rebranding in October 2019.